School of Medicine


Showing 1-8 of 8 Results

  • David Iberri, MD

    David Iberri, MD

    Clinical Assistant Professor, Medicine - Hematology

    Bio Dr. Iberri is a medical oncologist and hematologist who specializes in the treatment of hematologic malignancies. His clinical practices runs the gamut of malignant and non-malignant hematologic disorders including acute and chronic leukemias, multiple myeloma and lymphomas, and bleeding and thrombotic disorders. He is actively involved in clinical trials evaluating novel agents in hematologic malignancies. His research interests are in the development and application of biomarkers to select patients most likely to benefit from therapy.

  • Fumiaki Ikeno

    Fumiaki Ikeno

    Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine

    Bio Program Director (U.S) Japan Biodesign, Stanford Biodesign
    Cardiovascular Medicine, Stanford University


    Dr. Ikeno is a Research Associate, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.

    After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.

    Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.

    Contact Information


    Falk CVRC CV007
    300 Pasteur Drive
    Palo Alto, CA 94305-5406

  • Alvan Ikoku

    Alvan Ikoku

    Assistant Professor of Comparative Literature and of Medicine (General Medical Disciplines)

    Current Research and Scholarly Interests Ikoku's research traces confluences in science and literature that have long constituted modern medical and ethics discourse — dating from the mid-nineteenth century to the present period, and particularly where Africa and its diaspora are points of representation

    His scholarship has thus been in three areas. First, work that details the place of colonial, postcolonial, and world literatures in the evolution of tropical medicine and global health as medical fields, with writing on malaria and Africa as a primary focus. His current book, Forms of Global Health, and a forthcoming article, 'Reading Malaria Literature,' are part of this research, as is previous writing for the World Health Organization. Second, a series of long articles that detail efforts by writers of African descent to examine space, race and gender as genres of self-governance. And third, work that traces the emergence of modern fiction as an alternative mode for ethical thought regarding humane care and human subjects research. Here, he has published with Virtual Mentor as well as Narrative Inquiry in Bioethics, and he is developing a second book project on the Literature of Human Experimentation.

    Finally, Ikoku's research has been supported by the Mellon Foundation, the American Council of Learned Societies, the Institute for Social and Economic Research and Policy, Columbia University Research Grants, the Marjorie Hope Nicolson Fellowship, and the Rhodes Trust.

  • Erik Ingelsson

    Erik Ingelsson

    Professor of Medicine (Cardiovascular Medicine)

    Current Research and Scholarly Interests I am interested in the link between metabolic disturbances, such as obesity and insulin resistance, and the development of cardiovascular disease. My research is translational and interdisciplinary, combining methods from the molecular epidemiology field with in vivo and in vitro work to reach new insights into the pathophysiology of cardiovascular disease and related conditions, identification of new biomarkers for improved risk prediction, and discovery of novel drug targets.

  • John P.A. Ioannidis

    John P.A. Ioannidis

    C. F. Rehnborg Professor in Disease Prevention in the School of Medicine and Professor of Health Research and Policy (Epidemiology) and, by courtesy, of Statistics

    Current Research and Scholarly Interests Meta-research
    Evidence-based medicine
    Clinical and molecular epidemiology
    Human genome epidemiology
    Research design
    Reporting of research
    Empirical evaluation of bias in research
    Randomized trials
    Statistical methods and modeling
    Meta-analysis and large-scale evidence
    Prognosis, predictive and personalized medicine and health
    Sociology of science